Thormann J, Kramer W, Schlepper M
Z Kardiol. 1981 May;70(5):385-93.
AR-L115 has been shown to substantially improve myocardial pump function in patients (pts) with advanced congestive cardiomyopathy by i.v. and by p.o.-route. Since AR-L115 effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CSF) are unknown, the hemodynamic myocardial metabolic and ECG-responses to AR-L115 (2 mg/kg BW bolus) were monitored at the 9, 14 and 19-min interval in 7 patients coronary 3-vessel disease, exhibiting ischemia during pacing stress only. Maximal responses occurred at the 14th min after AR-L115. THere were (average) increases in cardiac index by 30%, in heart rate by 19%, in CSF by 39%, in MVO2 by 34%, and in dp/dt max by 27%. There were (average) decreases in peak systolic pressure by 13%, in PCW by 30%, in LVEDP by 42%, in systemic vascular resistance by 34%, and in coronary vascular resistance by 37%. All changes were significant (p less than 0.05). Unchanged (p greater than 0.05) remained myocardial lactate extraction, stroke work index, and stroke-index. The only moderate increase in MVO2 is possibly explained in that the increase in contractility was a least partially offset by the reductions in pre- and after load. The AR-L115-induced improved pump function was accompanied by moderate increases in MVO2 and CSF, but without evidence of myocardial ischemia.
AR-L115已被证明可通过静脉注射和口服途径显著改善晚期充血性心肌病患者的心肌泵功能。由于AR-L115对心肌耗氧量（MVO2）和冠状动脉血流量（CSF）的影响尚不清楚，因此在7例仅在起搏应激时出现缺血的冠状动脉三支病变患者中，于9、14和19分钟间隔监测了AR-L115（2mg/kg体重推注）对血流动力学、心肌代谢和心电图的反应。AR-L115给药后第14分钟出现最大反应。心脏指数平均增加30%，心率增加19%，CSF增加39%，MVO2增加34%，dp/dt max增加27%。收缩压峰值平均降低13%，肺毛细血管楔压降低30%，左心室舒张末压降低42%，体循环血管阻力降低34%，冠状动脉血管阻力降低37%。所有变化均具有显著性（p<0.05）。心肌乳酸摄取、每搏功指数和每搏指数保持不变（p>0.05）。MVO2仅适度增加，这可能是因为收缩力的增加至少部分被前负荷和后负荷的降低所抵消。AR-L115诱导的泵功能改善伴随着MVO2和CSF的适度增加，但没有心肌缺血的证据。
